Background-In disease of the femoropopliteal artery, paclitaxel-coated balloon (PCB) therapy improved angiographic outcomes as compared with uncoated balloon (UCB) angioplasty. Nevertheless, it remains uncertain whether PCB may reduce the need for reintervention. Methods and Results-We searched Medline, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), scientific session abstracts, and relevant web sites for trials of PCB versus UCB angioplasty. Key words were: "superficial femoral artery," "popliteal artery," "angioplasty," "drug-eluting balloon," "paclitaxel-eluting balloon," and "randomized trial." Inclusion criteria were: (1) randomized design; (2) intention-to-treat analysis; and (3) ≥6-month follow-up. Exclusion criteria were: (1) vessel treated other than femoropopliteal artery; (2) device used other than PCB/UCB; and (3) irretrievable or duplicated data. No restrictions (language, publication date, or status) were applied. The primary end point was target lesion revascularization. Secondary end points were: angiographic binary restenosis and late lumen loss and all-cause mortality. A total of 381 patients enrolled in 4 randomized trials were included (PCB, n=186 versus UCB, n=195). Median follow-up was 10.3 months. Angioplasty with PCB versus UCB reduces target lesion revascularization (12.2% versus 27.7%; OR, 0.22; 95% CI, 0.13-0.38; P<0.00001), angiographic restenosis (18.7% versus 45.5%; OR, 0.26; 95% CI, 0.14-0.48; P<0.0001), and late lumen loss (range, −0.05 to 0.50 mm versus 0.61-1.7 mm; weighted mean difference, −0.75 mm; 95% CI, −1.06 to −0.45; P<0.00001). No mortality difference was observed for PCB versus UCB (2.1% versus 3.2%; OR, 0.99; 95% CI, 0.39-2.49; P=0.98). Conclusions-In femoropopliteal arterial disease, PCB therapy is associated with superior antirestenotic efficacy as compared with UCB angioplasty with no evidence of a differential safety profile. (Circ Cardiovasc Interv. 2012;5:582-589.)
P ercutaneous transluminal balloon angioplasty represents a widely used revascularization strategy for patients with atherosclerotic peripheral artery disease. 1 In this vascular bed, different revascularization strategies have been associated with unsatisfactory clinical outcomes. 1 Among these, uncoated balloon (UCB) angioplasty has demonstrated reduced efficacy both at acute (vessel ruptures or recoil, flow-limiting dissections, suboptimal results) and midterm follow-up (rapid restenotic occlusion of the target vessel). 1, 2 Recently, percutaneous balloon catheters coated with antiproliferative drugs have been developed with the purpose of reducing restenosis after percutaneous intervention in peripheral vessels. 3 After positive preliminary experience in animal models, 4, 5 paclitaxel-coated balloon (PCB) therapy was tested against UCB angioplasty in patients with femoropopliteal artery (FPA) atherosclerotic disease. 6, 7 Although late lumen loss (LLL) was significantly reduced, the small number of patients limited the relevance of final results. 6, 7 In addition, more recent studies did not confirm the evidence of less target lesion revascularization (TLR) associated with PCB use. 8, 9 As a result, it remains a matter of some debate whether the use of PCB for FPA percutaneous revascularization may lower the risk of reinterventions. 2 Indeed, any such benefit may have considerable implication for the costs associated with peripheral artery disease and its complications.
Against this background, we performed a meta-analysis of randomized trials investigating outcomes associated with PCB versus UCB angioplasty for FPA disease.
Methods

Search Strategy and Selection Criteria
We searched Medline, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), scientific sessions abstracts, and relevant web sites without language, publication date, or publication status restrictions. Reference lists of the eligible studies and previous reviews were checked to identify further evaluable articles. The last search was run on December 2011. Search terms included the key words and the corresponding Medical Subject Headings (MeSH) for: "superficial femoral artery," "popliteal artery," "angioplasty," "drugeluting balloon," "paclitaxel-eluting balloon," and "randomized trial." Inclusion criteria were: (1) randomized design; (2) intention-to-treat analysis; and (3) ≥6-month follow-up. Exclusion criteria were: (1) vessel treated other than FPA; (2) device used other than PCB/UCB; and (3) irretrievable or duplicated data.
Data Collection and Assessment of Risk of Bias
Two investigators (S.C. and R.A.B.) independently assessed reports for eligibility at the title and/or at abstract level with divergences resolved by a third investigator (M.F.). Studies that met inclusion criteria were selected for further analysis. The risk of bias was evaluated by the same 2 authors in accordance with The Cochrane Collaboration method 10 based on the following methodological items: adequacy of random sequence generation and allocation concealment, blinding (at participant, personnel, or outcome assessors level), incomplete outcome data depiction, freedom from selective outcome report, and adequate description of sample size calculation. Formal quality score adjudication was not used, because previous investigations failed to demonstrate its value. 11
Outcome Variables
The primary outcome of this meta-analysis is TLR. Secondary outcomes are: binary restenosis and LLL at 6-month angiographic surveillance and mortality at the longest available follow-up. All end points were evaluated according to per-protocol definitions (onlineonly Data Supplement Table I ).
Statistical Analysis
Statistical analysis was performed with RevMan software (Review Manager [RevMan], Version 5.1; The Cochrane Collaboration, Copenhagen, Denmark), Stata 11.0 statistical software (STATA Corp, College Station, TX), and EXACTMA program (available at www. sph.emory.edu/~haustin/exactma.html). OR, weighted mean difference, and 95% CIs were used as a summary statistic. Mantel-Haenszel (M-H) fixed and random (DerSimonian and Laird) effects model were used to calculate pooled OR for categorical and weighted mean difference for continuous variables. According to the M-H method, treatment effect could not be assessed in trials in which no event was reported within groups. For trials in which only one of the treatment groups had no events of interest, the treatment effect estimate and its SE were approximated from 2×2 contingency tables after adding 0.5 to each cell. 12 Because these approximations may have a major impact on the results when the outcomes are rare, the ORs for categorical outcomes were calculated using the exact conditional likelihood method (exact) without approximation from 2×2 contingency tables according to Martin and Austin. 13 The risk estimates were reported as both approximated (OR [M-H] ) and nonapproximated (OR [exact] ). In case of statistical significance, the number needed to treat with relative CI was provided, if appropriate. The χ 2 test (P<0.01) and the I 2 statistic were calculated to test the statistical evidence of heterogeneity across the studies. As a guide, I 2 values <25% indicated low, 25% to 50% moderate, and >50% high heterogeneity. 10 Visual inspection of funnel plot asymmetry was performed to address for possible small-study effect as well as the Egger and Begg test 14 to test for publication bias to overcome any subjective evaluation. In case of variability of risk estimates between the M-H fixed-and random-effects model, these latter were selected as the most conservative option. The random-effects model takes into account the mean of a distribution of effects across studies and provides wider CIs for the regression coefficients than fixed-effect analysis if residual heterogeneity exists. The weight used for each trial was the inverse of the sum of the within trial variance and the residual between trial variance. To estimate the additive (between-study) component of variance, τ-2, the restricted maximum likelihood method, was used to take into account the occurrence of residual heterogeneity. A random effect
WHAT IS KNOWN
• In disease of the FPA, balloon angioplasty is limited by restenosis.
• PCB therapy improves angiographic outcomes compared with UCB angioplasty, but whether this translates into a reduced need for reintervention remains uncertain.
WHAT THE STUDY ADDS
• The angiographic superiority of PCB versus UCB angioplasty is matched by the reduction in the risk of TLR.
• Drug-coated balloon therapy should be tested in future investigations of different revascularization strategies in disease of the FPA. metaregression analysis was conducted to estimate the extent to which including 3 covariates-the nature of the study with respect to publication status (full-length article/meeting presentation), sample size (≥100 patients versus <100 patients), and blinding (single/double)-might have influenced the treatment effect. Finally, an influence analysis, in which meta-analysis estimates are computed omitting one study at time, was performed.
The study was performed in compliance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement. 15
Results
Eligible Studies
We screened the title and/or the abstract of 95 potentially eligible publications (Figure 1 ). Of these, 87 citations were excluded because they were not relevant to this study or duplicated. Thus, 8 studies were assessed for eligibility and 4 studies were eliminated because inclusion criteria were not met (onlineonly Data Supplement Table II ). Finally, 4 trials (2 full-length articles, 6,7 2 meeting presentations, 8, 9 n=433 patients) were included in the meta-analysis. The interobserver agreement for study selection was good with a κ value of 0.87.
The main characteristics of the included studies are reported in Table 1 . Briefly, patients with symptomatic FPA disease (Rutherford Class 1 6,7 or 2-5 8, 9 ) and ≥70% stenosis or occlusion evidence were randomized to PCB or UCB angioplasty. Balloon catheters used were coated with paclitaxel (at a dose of 3 μg/mm 26, 7, 9 or 2 μg/mm 28 of balloon surface) or uncoated. Drug was directly delivered from balloon surface into the vessel wall without a carrier 7 or with a vehicle (contrast medium, 6 urea 9 ); in one trial, the compound used is not described. 8 Device descriptions are summarized in online-only Data Supplement  Table III . One study 6 included a third treatment arm (n=52, paclitaxel addition to angiographic contrast medium), which was not included in our analysis. Thus, 381 patients (186 randomized to PCB and 195 randomized to UCB) entered final calculations. Patients with previous angioplasty (plus stent or not) were included. The main exclusions criteria in the included trials were in-/outflow disease and acute symptoms onset or FPA thrombosis. Provisional bare-nitinol stenting was allowed in case of suboptimal result after dilation. In one trial, 8 all cases underwent per-protocol predilation with an undersized UCB followed by randomization to PCB or UCB. All patients received active or control treatment on top of medical therapy. Details of postprocedural antiplatelet management was available in all trials but one. 9 Clinical features of well-matched typical peripheral artery disease population and treatment groups were well paired among studies. For PCB versus UCB angioplasty arms, mean age ranged from 67 to 71 years and from 69 to 71 years, respectively, whereas mean lesion length from 4.0 to 8.1 mm and from 4.2 to 8.0 mm, respectively. Median follow-up was 10.3 months. In all studies, LLL (mm) at 6-month angiographic follow-up was the primary end point. The risk of bias among studies is reported in Table 2 .
Clinical and Angiographic End Points
Data on TLR were available for a total of 360 patients (94.4%) and occurred in 90 patients (25%). A significant TLR reduction was found with PCB versus UCB (12.2% versus 27.7%; OR [M-H] , 0.23; 95% CI, 0.13-0.40; P<0.00001; number needed to treat, 4; 2.9-5.9; Figure 2A ). There was low heterogeneity across the trials (I 2 =6%, P for heterogeneity=0.36). The exact method confirmed these results (OR [exact] , 0.22; 0.13-0.38; P<0.00001; P for heterogeneity=0.35).
Data on angiographic restenosis were available for 233 participants (58.5%, 3 trials 6,7,9 ) and occurred in 76 patients (32.6%). A higher efficacy of PCB versus UCB was reported (18.7% versus 45.5%; OR [M-H] , 0.26; 0.14-0.48; P<0.0001; number needed to treat, 4; 2.6-6.6; Figure 3A ). There was no heterogeneity across the trials (I 2 =0%, P for heterogene-ity=1.00). The exact method confirmed these results (OR [exact] , 0.26; 0.14-0.48;, P<0.0001; P for heterogeneity=0.99). Data on LLL were available in 307 patients (80.5%). The superiority of PCB against UCB in terms of LLL was demonstrated (range, −0.05 to 0.50 versus 0.61-1.7 mm; weighted mean difference, −0.75; −1.06 to −0.45; P<0.00001; Figure 3B ). There was low heterogeneity across the trials (I 2 =24%, P for heterogeneity=0.27).
Data on all-cause mortality were available in 368 participants (96.5%) and occurred in 18 patients (4.8%). No difference was observed with PCB versus UCB (2.1% versus 3.2%; OR [M-H] , 1.04; 0.34-3.18; P=0.95). There was low heterogeneity across the included trials (I 2 =11%, P for heterogene-ity=0.34; Figure 3C ). The exact method confirmed these results (OR [exact] , 0.99; 0.39-2.49; P=0.98; P for heterogeneity=0.22). Figure 2B shows the funnel plot distribution for primary end point: the SE of the lnOR was plotted against the OR of TLR. Both Egger (P=0.44) and Begg (P=0.73) tests could validate the absence of bias due to small study effects. Moreover, no significant influence of prespecified covariates on the treatment effect was observed, including the publication status (P=0.32), sample size (P=0.22), and blinding (P=0.31). Influence analysis demonstrated that no single study significantly altered the summary ORs for the primary end point, because one at a time study omission did not result in a movement of the point estimate outside the 95% CI.
Small Study Effects, Sensitivity, and Influence Analyses
Discussion
In the present article, we report a meta-analysis of randomized trials assessing outcomes of PCB versus UCB angioplasty in patients undergoing revascularization for FPA disease. The salient findings are: (1) the revascularization with PCB is associated with lower TLR risk when compared with UCB angioplasty; (2) PCB significantly reduces LLL and restenosis at 6-month angiographic follow-up; (3) the use of PCB versus UCB has no impact on mortality hazard; and (4) the internal validity of the observations was supported by low heterogeneity across the trials for all outcomes assessed and lack of evidence of influence or publication bias. The findings from the present study may be considered important for at least 2 principal reasons.
First, despite encouraging results from a number of randomized controlled trials with drug-coated balloons, whether these devices reduce the risk of reinterventions remains a subject of considerable debate and the penetration of these devices in routine clinical practice varies broadly. 3 In fact, the debate over the efficacy of drug-coated balloons in the specific setting of disease of the FPA might be regarded as a case in point. Although initial studies have been able to document improvement in angiographic end points, findings in relation to a reduction in reinterventions were inconsistent. [6] [7] [8] [9] This might be attributable to a lack of statistical power in individual trials and this was an important motivation in undertaking our analysis. Moreover, although measures of neointimal inhibition are validated end points that can accurately predict TLR occurrence, 16 it is not infrequent that surrogate outcomes do not reflect endpoints occurrence. 17 In light of these issues, in the present study, the observed absolute risk reduction in TLR with PCB therapy (25.5%), in parallel with an improvement in angiographic restenosis (26.7%) as well as in LLL associated with PCB use, may be regarded as an important finding. Moreover, available data showed that most of the repeat procedures was driven by clinical complaints rather than by the "oculostenotic reflex." 6, 7 Furthermore, the consistent and significant TLR risk reduction with PCB across the included trials supports the relevance of these observations. Second, the demonstration of a clear reduction in reinterventions with PCB therapy is an important argument when we consider the optimal interventional approach for patients with obstructive disease of the FPA. In particular, the role of adjunctive stenting should be reconsidered. It is a feature of angioplasty trials that, in case of suboptimal result or complication after dilation (eg, flow-limiting dissection), crossover to stenting is necessary in a significant proportion of cases (the so-called provisional stenting strategy). 18, 19 Indeed, among included trials in the current analysis, this percentage ranged from 4% to 21% and from 14% to 34% in PCB versus UCB groups, respectively. Although it is common sense that stents provide an additional acute safety benefit over angioplasty in sealing intimal lesions and residual dissections after plain vessel dilation, an additional motivation for crossover to stenting is the belief that the suboptimal acute results will translate into inacceptable rates of patency over the medium term. However, the persisting vascular effects of drug-coated balloon therapy along with the improved rates of clinical restenosis with PCB in the current study may mean that the threshold for stenting with PCB therapy is higher. Any potential "stent-sparing" effect is of particular relevance in these patients due to the typically diffuse nature of FPA disease burden and the adverse effects of long-segment stenting. 1, 20 Third, it is important to question whether UCB remains a valid comparator in current randomized clinical trials. Contemporary trials of novel interventions in disease of the FPA continue to use UCB control arms. 18, 19 Although our data suggest that the overall relevance of such performed studies be questioned, some may argue that these studies reflect the low penetration of PCB in daily practice owing to the lack of a solid evidence base. Moreover, in future trials it might be desirable to study the effect of dual strategies such as PCB plus stenting to improve outcomes in peripheral revascularization both in de novo as well as in restenotic lesions.
Study Limitations
There are a number of limitations inherent in the current analysis that should be acknowledged. First, this is a metaanalysis performed on study-level data. Although some investigators may prefer patient-level analyses, we believe that the questions under consideration are reliable answered by a meta-analysis of aggregate data. 21 Second, the duration of follow-up was limited to a median of 10.3 months. Although a longer duration of follow-up may be desirable, at a mechanistic level, it is likely that arterial healing after angioplasty is complete at 6 months. Moreover, available data on limited numbers of patients suggest that PCB clinical superiority remains durable out to 24 months. 6, 7, 22 Third, the clinical impact of PCB versus UCB therapy cannot be fully explored through TLR and death risk estimates only; indeed, the painfree walking distance, the change in the Rutherford class, the risk of limb-specific reinterventions, the grade of wound healing, and the amputation-free survival were not assessable in the current analysis. In line with these arguments, the exclusion of patients with severely impaired arterial outflow precluded meaningful assessment of the impact of PCB on outcomes such as amputations. Notwithstanding this, what data are available from previous studies 6,7,9 reported a very low risk and wide CIs for this latter outcome (1.5% versus 1.5%; OR [exact] , 1.02; 0.18-5.89; P=0.98; PCB versus UCB, respectively) suggesting that larger samples are required to extend the findings of our study to broader outcomes in patients with critical limb ischemia. Fourth, the current analysis included trials using different drug-coated balloons. Although the differences in drug dose alone (2 μg/mm 2 or 3 μg/mm 2 of balloon surface) may not influence comparative efficacy, 23 the importance of differences in excipient coatings used to facilitate drug loading and delivery should be considered. 24 Fifth, the influence of protocol-mandated angiographic follow-up should be considered. Although this may magnify differences in absolute revascularization across groups, the relative differences are likely to be unaffected. Finally, recent technological and pharmacological innovations 19, 25, 26 might have improved revascularization efficacy in peripheral artery disease; in this regard, the efficacy of PCB as compared with newer drug-eluting stent devices needs to be assessed in specifically designed studies.
Conclusions
The results of the present analysis showed that PCB in comparison with UCB angioplasty offers enhanced antirestenotic efficacy in patients with femoropopliteal disease. There was no evidence to support adverse safety concerns. The impact of these findings in more challenging populations and the role of PCB with respect to other therapies such as stenting need to be addressed in specifically designed trials.
